AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Black Diamond Therapeutics Inc (NASDAQ:BDTX)
2.525 USD
+0.065 2.642%| Previous Close (in USD) | 2.46 |
|---|---|
| Change | +0.065 2.642% |
| 52 W H/L (in USD) | 7.660/2.310 |
| EBITDA (in USD) | -81.017M |
| PE Ratio | -- |
| Volume | 629234 |
| Diluted Eps TTM | -1.33 |
| Total Assets (in USD) | 158.567M |
|---|---|
| Total Liabilities (in USD) | 41.831M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 56.221M |
| Market Cap (in USD) | 135.238 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
One Main Street, Cambridge, MA, United States, 02142
617 252 0848
Employees: 54
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. David M. Epstein Ph.D. | Co-Founder, Pres, CEO & Director | 1959 |
| 2. | Dr. Fang Ni Pharm.D. | CFO, Principal Financial Officer and Chief Bus. Officer | 1987 |
| 3. | Mr. Brent Hatzis-Schoch Esq., J.D. | COO & Gen. Counsel | 1965 |
| 4. | Dr. Elizabeth Buck Ph.D. | Co-Founder & Chief Scientific Officer | 1975 |
| 5. | Ms. Erika Jones | VP of Fin., Corp. Controller & Principal Accounting Officer | 1985 |
| 6. | Ms. Elizabeth L. Montgomery | Chief People Officer | 1972 |
| 7. | Dr. Christopher D. Roberts Ph.D. | Advisor | 1970 |
| 8. | Mr. Tai-An Lin Ph.D. | Sr. VP of Translational Science & Discovery Biology | NA |
| 9. | Dr. Sergey Yurasov M.D., Ph.D. | Chief Medical Officer | 1969 |
| 10. | Ms. Melanie Morrison | Sr. VP of Devel. Operations | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.070 1.581% | 68.76 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+2.420 3.640% | 68.9 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+2.740 0.618% | 442.99 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.606 0.500% | 521.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -88.919M | -125.596M | -67.254M | -35.258M | -8.931M |
| Minority Interest | - | - | - | - | - |
| Net Income | -84.52M | -123.203M | -65.479M | -41.143M | -8.931M |
| Selling General Administrative | 28.391M | 30.043M | 21.361M | 7.579M | 1.954M |
| Gross Profit | - | - | - | - | - |
| Reconciled Depreciation | 0.508M | 0.205M | 0.052M | 0.047M | 0.044M |
| Ebit | -92.828M | -126.872M | -69.57M | -8.904M | -8.916M |
| Ebitda | -95.06M | -125.596M | -67.253M | -22.939M | -8.872M |
| Depreciation And Amortization | -2.232M | 1.276M | 2.317M | -14.035M | 0.044M |
| Operating Income | -92.828M | -126.872M | -69.57M | -8.904M | -8.904M |
| Other Operating Expenses | 92.828M | 126.872M | 69.57M | 29.332M | 8.904M |
| Interest Expense | -3.909M | 1.276M | 0.001M | 0M | 0M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 2.031M | 3.464M | 4.041M | 0.461M | 0.004M |
| Net Interest Income | 2.031M | 3.464M | 4.04M | 0.461M | 0.004M |
| Income Tax Expense | -4.399M | -2.393M | -1.775M | 5.885M | -0.027M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 92.828M | 126.872M | 69.57M | 29.332M | 8.904M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 3.909M | 1.276M | 2.316M | -26.354M | -0.031M |
| Net Income From Continuing Ops | -91.169M | -125.596M | -67.254M | -35.258M | -8.931M |
| Net Income Applicable To Common Shares | -91.169M | -125.596M | -67.254M | -35.258M | -8.931M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 158.567M | 156.255M | 247.682M | 329.67M | 158.295M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 2.634M | 4.899M | 5.917M | 4.487M | 1.048M |
| Total Liab | 41.831M | 40.56M | 491.502M | 21.912M | 209.265M |
| Total Stockholder Equity | 116.736M | -334.989M | -243.82M | -118.224M | -50.97M |
| Other Current Liab | 14.209M | 10.543M | 19.215M | 10.633M | 2.899M |
| Common Stock | 0.007M | 0.005M | 0.005M | 0.005M | 0.001M |
| Capital Stock | 0.007M | 0.005M | 0.005M | 0.005M | 0.001M |
| Retained Earnings | -417.431M | -334.989M | -243.82M | -118.224M | -50.97M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 1.168M | 1.239M | 9.731M | 2.417M |
| Cash | 56.221M | 34.315M | 65.799M | 34.605M | 154.666M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 19.646M | 15.261M | 23.642M | 14.218M | 4.863M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -30.923M | -6.175M | -37.339M | -25.864M | -154.666M |
| Short Term Debt | 3.113M | 2.841M | 0.32M | 1.047M | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 25.298M | 28.14M | 28.46M | 8.741M | - |
| Other Stockholder Equity | 534.187M | 1.819M | 0.409M | -330.289M | -200.573M |
| Property Plant Equipment | - | 2.587M | 30.74M | 8.787M | 0.164M |
| Total Current Assets | 134.034M | 127.706M | 209.786M | 319.554M | 154.666M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 75.179M | 88.492M | 143.987M | 280.462M | - |
| Net Receivables | - | - | - | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 2.324M | 1.877M | 4.107M | 2.538M | 1.964M |
| Accumulated Other Comprehensive Income | -0.027M | -1.824M | -0.414M | 0.614M | -0.001M |
| Non Currrent Assets Other | 0.823M | 1.168M | 7.156M | 1.329M | 3.465M |
| Non Current Assets Total | 24.533M | 28.549M | 37.896M | 10.116M | 3.629M |
| Capital Lease Obligations | 25.298M | 28.14M | 28.46M | 8.741M | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 53.549M | 133.323M | -281.691M | -281.549M | -0.076M |
| Total Cashflows From Investing Activities | 53.366M | 130.613M | -281.691M | -0.021M | -0.076M |
| Total Cash From Financing Activities | 0.177M | 0.729M | 214.944M | 127.756M | 52.312M |
| Net Income | -91.169M | -125.596M | -67.254M | -35.258M | -8.931M |
| Change In Cash | -31.539M | 31.194M | -118.893M | 103.061M | 43.782M |
| Begin Period Cash Flow | 67.022M | 35.828M | 154.721M | 51.66M | 7.878M |
| End Period Cash Flow | 35.483M | 67.022M | 35.828M | 154.721M | 51.66M |
| Total Cash From Operating Activities | -85.082M | -100.148M | -52.146M | -24.674M | -8.454M |
| Depreciation | 0.508M | 0.205M | 0.052M | 0.047M | 0.044M |
| Other Cashflows From Investing Activities | 0.009M | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | 0.177M | 0.729M | 214.944M | 129.499M | 52.312M |
| Other Cashflows From Financing Activities | 53.366M | 0.729M | 1.1M | -1.743M | 52.312M |
| Capital Expenditures | 0.192M | 2.71M | 0.142M | 0.021M | 0.076M |
| Change In Working Capital | -9.901M | 7.02M | 5.042M | 0.463M | 0.354M |
| Other Non Cash Items | 3.283M | 2.007M | 0.524M | 6.431M | 0.015M |
| Free Cash Flow | -85.274M | -102.858M | -52.288M | -24.695M | -8.53M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BB Biotech AG Ord | 8 months ago | 8517839 |
| 2. | T. Rowe Price US Small-Cap Core Equity | 8 months ago | 2508412 |
| 3. | T. Rowe Price Small-Cap Stock | 7 months ago | 2504276 |
| 4. | T. Rowe Price Small-Cap Value | 7 months ago | 2425602 |
| 5. | Vanguard Total Stock Mkt Idx Inv | 7 months ago | 1329831 |
| 6. | T. Rowe Price Instl Small-Cap Stock | 7 months ago | 1236268 |
| 7. | T. Rowe Price U.S. SC Value Eq Tr-Z | 8 months ago | 1234985 |
| 8. | T. Rowe Price U.S. SC Core Eq Tr-Z | 8 months ago | 1208091 |
| 9. | iShares Russell 2000 ETF | 6 months ago | 1117019 |
| 10. | BlackRock Health Sciences Term Trust | 9 months ago | 866005 |
| 11. | T. Rowe Price US Smlr Cm Eq A USD | 7 months ago | 725115 |
| 12. | Vanguard Institutional Extnd Mkt Idx Tr | 7 months ago | 600308 |
| 13. | Fidelity Small Cap Index | 8 months ago | 405425 |
| 14. | Kennedy Micro Cap | 8 months ago | 379206 |
| 15. | State St Russell Sm/Mid Cp® Indx NL Cl C | 7 months ago | 291565 |
| 16. | iShares Russell 2000 Growth ETF | 6 months ago | 253432 |
| 17. | Fidelity Extended Market Index | 7 months ago | 250875 |
| 18. | Kennedy Extended Small Cap | 8 months ago | 226741 |
| 19. | T. Rowe Price Small-Cap Value Equity | 8 months ago | 201600 |
| 20. | Northwestern Mutual Ser Small Cap Value | 8 months ago | 201600 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | T. Rowe Price Investment Management,Inc. | 8 months ago | 10734389 |
| 2. | Bellevue Group AG | 8 months ago | 8517839 |
| 3. | Vestal Point Capital LP | 8 months ago | 5028500 |
| 4. | NEA Management Company, LLC | 8 months ago | 4448757 |
| 5. | BlackRock Inc | 11 months ago | 3217128 |
| 6. | Vanguard Group Inc | 8 months ago | 2318011 |
| 7. | TANG CAPITAL MANAGEMENT LLC | 8 months ago | 1370209 |
| 8. | Geode Capital Management, LLC | 8 months ago | 944877 |
| 9. | ExodusPoint Capital Management, LP | 8 months ago | 872680 |
| 10. | State Street Corp | 8 months ago | 809196 |
| 11. | Citadel Advisors Llc | 8 months ago | 703704 |
| 12. | Point72 Asset Management, L.P. | 8 months ago | 697125 |
| 13. | Kennedy Capital Management Inc | 8 months ago | 657036 |
| 14. | Octagon Capital Advisors LP | 8 months ago | 594000 |
| 15. | Driehaus Capital Management LLC | 8 months ago | 555111 |
| 16. | T. Rowe Price Associates, Inc. | 8 months ago | 379944 |
| 17. | Northern Trust Corp | 8 months ago | 345114 |
| 18. | Connor Clark & Lunn Inv Mgmt Ltd | 8 months ago | 284153 |
| 19. | Goldman Sachs Group Inc | 8 months ago | 281016 |
| 20. | Boxer Capital LLC | 8 months ago | 506000 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...